Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Danaher Corporation (DHR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Danaher Corporation — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.99 (market cap $4.49B), while Danaher Corporation trades at $190.62 (market cap $137.44B). The key difference: Danaher Corporation is far larger — about 30.6× ACADIA Pharmaceuticals Inc.'s market cap, and Danaher Corporation pays a 0.82% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | DHR | |
|---|---|---|
Market Cap | $4.49B | $137.44B |
Sector | Health | Health |
52-Week High | $28.06 | $242.05 |
52-Week Low | $20.06 | $161.91 |
Enterprise Value | $3.69B | $150.22B |
Dividend Yield | — | 0.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Danaher (DHR) trades at $190.77, down 1.47% on the day, with a bullish technical outlook supported by moving averages and strong institutional support. The company maintains solid fundamentals with consistent earnings beats, a 14.89% net income margin, and positive cash flow of $2.54B in 2025. Recent developments include the Masimo acquisition approval and new product launches in the biotechnology segment.
The stock presents a compelling opportunity with 69% analyst buy ratings and a $214.73 price target suggesting 12.6% upside. Key risks include revenue stagnation from $24.6B in 2025 to projected $24.8B in 2026 and the recent $172.5M legal settlement over pandemic-era disclosures. Biotechnology segment growth at 7% remains a positive catalyst.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →
